TIDMVLG

RNS Number : 2514W

Venture Life Group PLC

20 December 2021

20 December 2021

Venture Life Group plc

("Venture Life" or the "Company")

Directorate Change

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, is pleased to announce that Mr Daniel Wells, appointed as Chief Financial Officer at the time of the trading update announcement on 1 December 2021, has joined the Board with immediate effect.

Further information on Daniel Wells

Daniel James Wells (aged 34) has in the last five years been a director of The Green (Stoke Park) Management Company Limited and is currently a director of Susandan Limited.

There is no further information on Daniel Wells required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information please contact:

 
  Venture Life Group PLC                            +44 (0) 1344 578004 
   Jerry Randall, Chief Executive Officer 
    Daniel Wells, Chief Financial Officer 
 
                                                      +44 (0) 20 7397 
    Cenkos Securities plc (Nomad and Broker)          8900 
   Stephen Keys / Camilla Hume 
   Russell Kerr / Michael Johnson (Sales) 
 
                                                      +44 (0) 20 7496 
    N+1 Singer (Joint Broker)                         3000 
   Shaun Dobson / Alaina Wong (Corporate Finance) 
   Jonathan Dighe (Sales)

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABLBDDIGDDGBG

(END) Dow Jones Newswires

December 20, 2021 11:13 ET (16:13 GMT)

Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Venture Life
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Venture Life